ライフサイエンスコーパス: polymyositis

1 tomyositis and, to a lesser degree, juvenile polymyositis.

2 versity Medical Center with the diagnosis of polymyositis.

3 vels lower than those in other patients with polymyositis.

4 high muscles seen on initial MRI represented polymyositis.

5 t be distinguished histologically early from polymyositis.

6 for inclusion body myositis and unresponsive polymyositis.

7 the determining factor, and in persons with polymyositis.

8 ses such as systemic lupus erythematosus and polymyositis.

9 s, one grade 4 polymyositis, and two grade 3 polymyositis.

10 ewly identified in a subset of patients with polymyositis.

11 d necrotizing myopathy with many features of polymyositis.

12 n only 1/28 patients with dermatomyositis or polymyositis.

13 tients are frequently misdiagnosed as having polymyositis.

14 autoimmunity in inclusion body myositis and polymyositis.

15 ermatomyositis, inclusion body myositis, and polymyositis.

16 ed therapeutic trials of dermatomyositis and polymyositis.

17 ypes in individuals with dermatomyositis and polymyositis.

18 (n = 71), systemic sclerosis 36.0% (n = 22), polymyositis 6.2% (n = 16), and adult Still's disease 0%

19 55.5 +/- 13.4 years,52% Dermatomyositis, 39% Polymyositis, 9% Necrotizing Myopathy) participated.

20 patients with dermatomyositis and some with polymyositis, a blood type 1 interferon-signature correl

21 10 children (9 with dermatomyositis, 1 with polymyositis; ages 4-15 years) twice in one day (morning

22 ponse may not be antigen driven, there is in polymyositis an overexpression of certain T-cell recepto

23 We conclude that patients with polymyositis and an excess of COX-negative muscle fibres

24 les were upregulated in IBM as compared with polymyositis and controls (p < 0.01).

25 Both polymyositis and Crohn's ileocolitis responded well to c

26 (RA) (n = 80), Sjogren's syndrome (n = 30), polymyositis and dermatomyositis (n = 30), and progressi

27 omodulatory drugs are certainly effective in polymyositis and dermatomyositis despite the lack of ran

28 Various classification criteria for polymyositis and dermatomyositis have been suggested by

29 re is increasing evidence that patients with polymyositis and dermatomyositis have specific clinico-s

30 Studies in adults with polymyositis and dermatomyositis implicate interleukin-1

31 lieved that muscle weakness in patients with polymyositis and dermatomyositis is due to autoimmune an

32 unresponsive polymyositis than in responsive polymyositis and dermatomyositis patients.

33 itiation of therapy is essential, since both polymyositis and dermatomyositis respond to immunotherap

34 In the human inflammatory myopathies (polymyositis and dermatomyositis), the early, widespread

35 te diagnosis of inflammatory myopathy (i.e., polymyositis and dermatomyositis).

36 can often be found in serum of patients with polymyositis and dermatomyositis.

37 r idiopathic inflammatory myopathies such as polymyositis and dermatomyositis.

38 and includes pertinent data from adults with polymyositis and dermatomyositis.

39 l limitations and disability for adults with polymyositis and dermatomyositis.

40 A brief trial of azathioprine in polymyositis and eight studies using various treatments

41 cal IIM subclassifications: dermatomyositis, polymyositis and inclusion body myositis (IBM).

42 nflammatory muscle diseases dermatomyositis, polymyositis and inclusion body myositis are of unknown

43 and myeloid dendritic cells are abundant in polymyositis and inclusion body myositis muscle.

44 In polymyositis and inclusion body myositis, muscle fibers

45 e typically subdivided into dermatomyositis, polymyositis and inclusion body myositis.

46 In polymyositis and inclusion-body myositis, clonally expan

47 crotizing myopathy, inclusion body myositis, polymyositis and overlap myositis.

48 crotizing myopathy, inclusion body myositis, polymyositis and overlap myositis.

49 s mycophenolate mofetil is effective in both polymyositis and refractory dermatomyosits (including re

50 In polymyositis and sporadic inclusion body myositis, clona

51 igen(s) responsible for T-cell activation in polymyositis and sporadic inclusion-body myositis and th

52 -driven inflammatory cells that characterize polymyositis and sporadic inclusion-body myositis from t

53 In polymyositis and sporadic inclusion-body myositis, antig

54 se with clinical features of scleroderma and polymyositis and who was not on specific medications was

55 h rheumatoid arthritis, 1 with lupus, 1 with polymyositis, and 6 with EUCTD).

56 istocompatibility complex class I (43 IBM, 6 polymyositis, and 9 unclassifiable myositis), and 9 cont

57 ess with antigen-driven T cells identical to polymyositis, and a degenerative process in which beta-a

58 f patients with Duchenne muscular dystrophy, polymyositis, and compartment syndrome.

59 olated from samples of IBM, dermatomyositis, polymyositis, and control muscles were treated with reco

60 Inclusion body myositis, polymyositis, and dermatomyositis are three distinct cat

61 ecent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests a

62 he inflammatory myopathies (dermatomyositis, polymyositis, and inclusion body myositis) remains obscu

63 tory myopathies, comprising dermatomyositis, polymyositis, and inclusion body myositis.

64 major and distinct subsets: dermatomyositis, polymyositis, and inclusion-body myositis.

65 whereas their prevalence in dermatomyositis, polymyositis, and other neuromuscular disorders appeared

66 divided into three groups: extreme exercise, polymyositis, and seizures.

67 us, Sjogren's disease, rheumatoid arthritis, polymyositis, and systemic sclerosis.

68 Classification systems of dermatomyositis, polymyositis, and the other idiopathic inflammatory myop

69 rade 3 interstitial pneumonitis, one grade 4 polymyositis, and two grade 3 polymyositis.

70 Chronic graft-versus-host disease-related polymyositis appears to be very similar to idiopathic my

71 Dermatomyositis and polymyositis are associated with cancer, but previous na

72 cells present in inclusion body myositis and polymyositis are primarily myeloid dendritic cells.

73 Although types of malignancy seen in DM and polymyositis are similar to those in the general populat

74 Dermatomyositis and polymyositis are treatable disorders of skeletal muscle.

75 similar mechanisms appear to be involved in polymyositis associated with HTLV-I (human T cell lympho

76 transthyretin amyloidosis) can mimic that of polymyositis, but also shows that unique findings on MRI

77 rior chamber uveitis, and steroid-responsive polymyositis confirmed by electrophysiologic studies.

78 n the past 2 years, with particular focus on polymyositis, dermatomyositis and inclusion body myositi

79 eterogeneous group of diseases that includes polymyositis, dermatomyositis, and inclusion body myosit

80 yositis syndromes (the most common forms are polymyositis, dermatomyositis, and inclusion body myosit

81 and 2B, Miyoshi myopathy, nemaline myopathy, polymyositis, dermatomyositis, and inclusion body myosit

82 the most common inflammatory myopathies are polymyositis, dermatomyositis, and inclusion body myosit

83 ed in patients with inclusion-body myositis, polymyositis, dermatomyositis, and neurogenic muscle atr

84 pus erythematosus, Wegener's granulomatosis, polymyositis, dermatomyositis, polyarteritis nodosa, or

85 ly associated with a subset of patients with polymyositis/dermatomyositis (PM/DM) complicated by inte

86 with SSc, systemic lupus erythematosus, and polymyositis/dermatomyositis (PM/DM) were evaluated for

87 to determine whether sera from patients with polymyositis/dermatomyositis (PM/DM) with or without int

88 se who had 45-55-kd bands, all patients with polymyositis/dermatomyositis (PM/DM), and a random selec

89 erythematosus, 121 with scleroderma, 86 with polymyositis/dermatomyositis [PM/DM]) and 248 Italian pa

90 cytoplasmic antibody-associated vasculitis, polymyositis/dermatomyositis, and primary Sjogren's synd

91 I, 1.10-1.27) and specific prior autoimmune (polymyositis/dermatomyositis, systemic sclerosis, autoim

92 nti-RHA was not observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheuma

93 tingly, similar to what is observed in human polymyositis/dermatomyositis, the mice developed a stron

94 ated 10 patients with histologically typical polymyositis except for an excess of muscle fibres with

95 ermatomyositis, inclusion body myositis, and polymyositis gained from large-scale microarray gene exp

96 cle biopsy in 2 patients in the unresponsive polymyositis group demonstrated histological features of

97 All patients with dermatomyositis and polymyositis (> or =15 years old) were identified by dis

98 patients with adult-onset dermatomyositis or polymyositis had a baseline assessment a median of 30 mo

99 137 of the 914 cases of polymyositis had cancer, which developed after diagnosis

100 patients with IIM, in particular those with polymyositis, had no strong disease associations with HL

101 Although inclusion body myositis and polymyositis have been characterized as cytotoxic CD8(+)

102 d cancer, which developed after diagnosis of polymyositis in 95.

103 bellar degeneration (PCD) in HL and dermato/ polymyositis in both HL and NHL, other PNSs are uncommon

104 losing spondylitis, psoriatic arthritis, and polymyositis, in 36 patients.

105 ) infection, studies into a primate model of polymyositis induced by HTLV-I may be particularly infor

106 Polymyositis is an uncommon disorder that can be misdiag

107 A breed-specific polymyositis is frequently observed in the Hungarian Viz

108 The relation with polymyositis is much weaker, if at all present.

109 rt here the first known case of inflammatory polymyositis leading to rhabdomyolysis in a male patient

110 previously healthy man presented with acute polymyositis leading to rhabdomyolysis.

111 ases, such as SLE, rheumatoid arthritis, and polymyositis may occur de novo or exacerbate.

112 c inflammatory myopathy (dermatomyositis and polymyositis) may have in certain instances extramuscula

113 y, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and th

114 lation alterations were observed in juvenile polymyositis (n = 5) and other IIMs (n = 9).

115 farction (n = 10), myonecrosis due either to polymyositis or crush injuries (n = 12), and septic shoc

116 A total of 37 patients with polymyositis or dermatomyositis were randomized (19 to c

117 milies with other siblings or relatives with polymyositis or dermatomyositis, and 2 families with inc

118 significant adverse effects in patients with polymyositis or dermatomyositis.

119 occur in approximately 25% of patients with polymyositis or dermatomyositis.

120 d systemic lupus erythematosus (SLE); 17 had polymyositis or dermatomyositis; 16 had scleroderma; eig

121 and in a similar percentage of patients with polymyositis or systemic sclerosis.

122 agnosed with either inclusion body myositis, polymyositis, or dermatomyositis.

123 ) age-matched patients with dermatomyositis, polymyositis, or necrotizing myopathy, and 0/20 (0%) age

124 itis, Sjogren's syndrome, dermatomyositis or polymyositis, or scleroderma were of borderline statisti

125 e of onset was 9 years older than a group of polymyositis patients with normal COX staining of muscle

126 lt or juvenile IIM, comprising patients with polymyositis (PM) (n=114), dermatomyositis (DM) (n=102),

127 Adults with refractory polymyositis (PM) and adults and children with refractor

128 of UK Caucasian patients have confirmed that polymyositis (PM) and dermatomyositis (DM) are not genet

129 markers in IBM compared with normal control, polymyositis (PM) and non-inflammatory dystrophy sample

130 vo in patients with dermatomyositis (DM) and polymyositis (PM) in order to evaluate the role of mitoc

131 Polymyositis (PM) is an autoimmune muscle disease charac

132 diffuse interstitial lung disease and either polymyositis (PM) or dermatomyositis (DM).

133 c controls, two dermatomyositis (DM) and two polymyositis (PM) patients was reverse transcribed and r

134 es, but occurred more often in patients with polymyositis (PM) than in those with dermatomyositis (DM

135 e episodes (MELAS), dermatomyositis (DM) and polymyositis (PM) using pairwise statistical comparison

136 the pathogenesis of the diverse entities of polymyositis (PM), dermatomyositis (DM), and inclusion b

137 echanisms were analysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and

138 from 44 patients with dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), myasth

139 scle disorders include Dermatomyositis (DM), Polymyositis (PM), Necrotizing Myositis (NM), and sporad

140 52), in the muscle biopsies of patients with polymyositis (PM), PM associated with human immunodefici

141 e dermatomyositis (DM), compared to juvenile polymyositis (PM), was assessed in 298 juvenile IIM pati

142 er ear disease among patients diagnosed with polymyositis (PM)/dermatomyositis (DM).

143 ctively from consecutive adult patients with polymyositis (PM; n = 134), dermatomyositis (n = 129), o

144 ients were carrying a diagnosis of infantile polymyositis prior to immunostaining studies.

145 ant association with ankylosing spondylitis, polymyositis, psoriasis, rheumatoid arthritis, sicca syn

146 patients with established dermatomyositis or polymyositis receiving chronic medical therapies who are

147 In both dermatomyositis and polymyositis, risk of malignant disease was highest at t

148 Sera from some patients with polymyositis-scleoderma overlap syndrome (PM-SCL) recogn

149 the 100 kDa antigenic component of the human polymyositis scleroderma (PMSCL) autoantigen, is a 3'-->

150 100, an autoantibody target in patients with polymyositis, scleroderma, or polymyositis-scleroderma o

151 The anti-polymyositis-scleroderma autoantibody is associated with

152 lated the rat (r) homologue of the human (h) polymyositis-scleroderma autoantigen (PM-Scl), which has

153 9 but not with human Ubc5, MyoD, Id3, or the polymyositis-scleroderma autoantigen.

154 te domain that is found also in Homo sapiens polymyositis-scleroderma overlap syndrome 100 kDa autoan

155 y autoimmune sera of patients suffering from polymyositis-scleroderma overlap syndrome.

156 eroderma autoantibody is associated with the polymyositis-scleroderma overlap syndrome.

157 patients with polymyositis, scleroderma, or polymyositis-scleroderma overlap syndrome.

158 The polymyositis/scleroderma autoantigen gene was overexpres

159 ividual cancer sites for dermatomyositis and polymyositis separately, using national cancer rates by

160 A polymyositis syndrome has been described as a rare compl

161 in inclusion body myositis and unresponsive polymyositis than in responsive polymyositis and dermato

162 leroderma; Sjogren Syndrome; dermatomyositis/polymyositis; unspecified/mixed CTD; other inflammatory

163 ted, the association of Crohn's disease with polymyositis varies in its complexity and severity.

164 Polymyositis was associated with a raised risk of non-Ho

165 sed genes and pathways identified in IBM and polymyositis were mostly comparable.

166 markers led to the suspicion of inflammatory polymyositis, which was confirmed by electromyography an

167 Polymyositis with mitochondrial pathology (PM-Mito) was

168 also modestly increased among patients with polymyositis, with an excess for some cancers.

169 dence of autoimmunity in dermatomyositis and polymyositis, with strong correlations between particula